to mean "rehabilitation or restoration of function," [6] quaternary prevention (P4) is defined as "action taken to identify patient at risk of over medicalization, to protect him from new medical invasion and to suggest to him interventions, which are ethically acceptable." [7] Quaternary prevention, in the context of GDM, includes action taken (or action that should be taken) to avoid unnecessary screening, overdiagnosis, inappropriate investigations, and unwarranted therapeutic measures in a healthy antenatal woman. Unfortunately, the GDM landscape, crowded with confusion and conflict in both diagnosis and management, [8] is fertile ground for these very phenomena.
Much of this doubt was created by findings of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, which led to formulation of the International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. These guidelines were extrapolated to women with gestation <24 weeks, who were not included in HAPO. This led to a tendency to overdiagnose and over-label healthy women with GDM during the first half of pregnancy. Hence, it becomes imperative to analyze current management practices in GDM from a quaternary prevention perspective [ Table 1 ].
pragmatIc approach for Quarternary preventIon

Frequency of screening
Over-screening is one of the cardinal targets of quaternary prevention. Although universal screening of GDM is widely accepted in India and other high-risk settings, the timing, frequency, and mode of testing is still open to debate. [8, 9] While glucose estimations are suggested in every trimester, it must be made clear that the first-trimester test is not to screen for GDM every trimester, it must be made clear that the first-trimester test is not to screen for GDM, but to detect preexisting diabetes. At the same time, repeated glucose determinations may be required in select patients, such as those with unexplained hydramnios or on antenatal corticosteroid therapy. [10] Mode of screening
The mode of screening is also a matter of controversy. One-step and two-step procedure, 1 h and 2 h postchallenge test, following glucose loads of either 50 g or 75 g, with or without fasting blood glucose estimation, in fasting or nonfasting state: [11] various options cause lack of consensus among GDM care providers, and can prevent effective quaternary prevention.
The need for HbA1c as a diagnostic test for GDM, although not endorsed by major opinion-making organizations, has been proposed by commentators as a means of identifying high-risk patients. [12] Its use (or misuse), too, must be addressed by quaternary prevention.
Diagnosis
The diagnostic cutoffs for GDM differ from those of diabetes mellitus and varies according to the screening method used. Use of lower cutoffs has been shown to increase the number of women labeled as having GDM, without causing a meaningful improvement or change in outcomes. On the other hand, use of higher cut-offs may increase specificity while lowering sensitivity to unacceptably low levels. [8] The issue is complicated by discussion surrounding relevance of data from global trials, and single country studies, to multiethnic groups. [12] Here, too, the concept of quaternary preventions needs to be invoked to protect patient well-being and outcomes.
Investigations
A label of GDM is accompanied by the prescription of more frequent health-care visits and investigations, including self-monitoring of blood glucose ultrasonography and cardiotocography, among others. [13, 14] All these interventions incur a cost, which is financial, physical, and emotional in nature. Visits to the antenatal care provider, diabetes specialist, and allied medical professionals cost time and money and may necessitate time off from work for both the patient and her attendant. Investigations impose a financial burden and may cause physical discomfort as well, for example, the finger pricks required for glucose monitoring.
Management
Diagnosis of GDM entails intensive management, which may include lifestyle modification, oral glucose lowering drugs, insulin, and obstetrics-related intervention. [15] Such medical "invasion" has the potential for side effects and may sometimes lead to a negative risk: benefit ratio. Management strategies are not limited to the antenatal period; they include care of the neonate, postpartum follow-up of the GDM mother, and long-term surveillance of the child born of a GDM-complicated pregnancy. [16, 17] The ethical tightrope
The concept of quaternary prevention rightly brings focus on a clinical, ethical, and medicolegal dilemma for GDM care providers. What definition of health should be followed while addressing GDM? Should a GDM caregiver hasten to help (Primum succurrere) by screening, diagnosing, labeling, and treating as many women as possible, or should she follow the dictum of primum non nocere and keep medical intervention (or invasion) to a minimum? [18] Should GDM management focus on biomedical attributes such as glucose levels, and exclude psychosocial aspects such as the stress associated with a GDM label? Should short-term maternofetal outcomes take precedence over remotely potential long-term metabolic complications?
pragmatIc approach
There is no single answer to these questions. The GDM care provider shoulders the challenging responsibility of helping the women with GDM decide the optimal course of action though a sensitive phase of life. [19] Such a responsibility is best discharged by a process of shared and informed decision-making in a patient centered, family centered, community-oriented, and culturally sensitive manner. This should simultaneously be supported by shared responsibility, including peers from the same specialty, and colleagues from complementary disciplines, including obstetrics, medicine, endocrinology, mental health, and social health.
While medical decisions should be data driven or evidence based. They should be open to modulation by psychological circumstances and sociophysical reality. [19] A patient who has a biomedical history suggestive of high risk of GDM, lives within accessible distance of health care, and has no financial constraints, should certainly undergo frequent screening, as suggested by guidelines. On the other hand, a relatively lower risk subject, who finds it difficult to avail of access, or afford modern health care, may be managed with less frequent investigations.
Once the patient crosses the therapeutic threshold of GDM, a management strategy has to be planned. The initial therapy (medical nutrition therapy [MNT] vs. MNT + oral antidiabetic drugs vs. MNT + insulin) has to be decided, along with the frequency of follow-up and expected line of intensification.
Ideally, these decisions should match pharmacology to pathophysiology while keeping sight of psychosocial limitations and strengths. A medically high-risk patient, who can willingly, and easily, return for frequent antenatal care visits, may be managed with relatively frequent visits and rapid intensification of pharmacological therapy. At the other end of the spectrum, a low risk patient, with weak risk of GDM according to history, low baseline HbA1c/fasting glycemia, inability, or lack of motivation to self-monitoring glucose and/or self-titrate therapy dose, and poor physical, financial, or socially approved access to the health-care system should be prescribed relatively less aggressive therapy with less frequent follow-up.
Summary
Any "medical invasion," whether labeling, diagnostic, or therapeutic, should be performed only if the cost-benefit ratio appears favorable. Such action should contribute to achieving better outcomes, both short-term and long-term, in the mother as well as offspring.
If we can ensure this, we will have ensured what we described as the core aim of medicine: Maintenance of health, and prevention of ill-health, in women with GDM.
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